Almotriptan in the treatment of migraine attacks in clinical practice: Results of the TEA 2000 observational study;Almotriptán en el tratamiento de los ataques de migraña en la práctica clínica: Resultados del estudio observacional TEA

Neurologia

Volumn 18, Issue 1, 2003, Pages 7-17

  Pascual, Julio ^a   Lainez J M ^b   Leira, R ^c   Titus, F ^d   Mateos, V ^e   Galvan J ^f  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c Instituto de Salud Carlos III   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f NONE   (Spain)

Author keywords

Almotriptan; Migraine

Indexed keywords

ALMOTRIPTAN;

ABDOMINAL PAIN; ADULT; ANXIETY; ARTICLE; ASTHENIA; CLINICAL PRACTICE; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FATIGUE; FEMALE; FOLLOW UP; HEART PALPITATION; HUMAN; HYPERTENSION; HYPESTHESIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MIGRAINE; NAUSEA; NERVOUSNESS; PARESTHESIA; PHARYNGITIS; RECURRENT DISEASE; SIDE EFFECT; SOMNOLENCE; SYNCOPE; TACHYCARDIA; THORAX PAIN; TREATMENT OUTCOME; VERTIGO; VISUAL DISORDER; VOMITING;

ADULT; CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; DRUG EVALUATION; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; SEROTONIN AGONISTS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 0242418185     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. Brain 1996;119:355-61.
2. Lavados PM, Tenhamm E. Epidemiology of migraine headache in Santiago, Chile: a prevalence study, Cephalalgia 1997;17:770-7.
3. Lipton RB, Stewart WF. Migraine headaches: epidemiology and comorbidity. Clin Neurosci 1998;5:2-9.
4. Launer U, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 1999;53:537-42.
5. Láinez JM. Prevalencia e impacto socioeconómico de la migraña, En: Láinez JM, editores. Diagnóstico diferencial y tratamiento de la jaqueca, Madrid: Ergón, 1998.
6. Monzón M J, Láinez MJ. Quality of life in migraine and chronic daily headache patients. Cephalalgia 1998;18:638-43.
7. Leira R, Láinez JM, Pascual J, Diez-Tejedor E, Morales F, Titus F, et al. Estudio español de calidad de vida en migraña (I). Perfil del paciente con migraña que acude a consultas de neurología. Neurología. 1998;13:287-91.
8. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999;159:813-8.
9. Dahlöf C. Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993;13:166-71.
10. Ferrari MD. Migraine. The Lancet 1998;351:1043-51.
11. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in Migraine. A comparative Review of Pharmacology, Pharmacokinetics and Efficacy. Drugs 2000;60:1259-87.
12. Humphrey PP, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 1991;12:444-6.
13. Dechant KL, Clissold SP. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1992;43:776-98.
14. Telf-Hansen P. Sumatriptan for the treatment of migraine attacks - a review of controlled clinical trials. Cephalalgia 1993;13:238-44.
15. Perry CM, Markham A. Sumatriptan. An updated review of its use in migraine. Drugs 1998;55 (6):889-922.
16. Bateman DN. Triptans and migraine. Lancet 2000;355:860-1.
17. Purdy RA. Evidence-based migraine therapy: learning needs and knowledge assessment. Cephalalgia 2000;20:5-9.
18. Salonen R. Drug comparisons: why are they so difficult? Cephalalgia 2000;20:25-32.
19. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-75.
20. Gras J, Bou J, Llenas J, Fernández AG, Palacios JM. Functional profile of almotriptan in animal models predictive of antimigraine activity. Eur J Pharmacol 2000;410:43-51.
21. Dodick DW. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache 2001;41:499-555.
22. Cabarrocas X, Salva M. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug. Cephalalgia 1997;17:421.
23. Robert M, Warrington SJ, Zayas JM, Cabarrocas X, Fernandez FJ, Ferrer P. Electrocardiographic effects and pharmacokinetics of oral almotriptan in healthy subjects. Cephalalgia 1998;18:406.
24. Pascual J, Falk RM, Piessens F, Prusinski A, Docekal P, Robert M, et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia 2000;20:588-96.
25. Cabarrocas X, Esbri R, Peris F, Ferrer P. Long-term efficacy and safety of oral almotriptan: interim analysis of a 1-year open study. Headache 2001;41:57-62.
26. Martínez E, Cabarrocas X, Peris F, Ferrer P, Luria X. Meta-analysis of the efficacy and safety of almotriptan in the treatment of migraine. Cephalalgia 1999;19:362.
27. Fleishaker JC, Ryan KK, Jansat JM, Carel BJ, Bell DJ, Burke MT, et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br J Clin Pharmacol 2001;51:437-41.
28. Fleishaker JC, Ryan KK, Carel BJ, Azie NE. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. J Clin Pharmacol 2001;41:217-23.
29. Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. Cephalalgia 2001;21:61-5.
30. Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther 2000;67:498-503.
31. Fleischhacker WW, Hummer M. Do phase III trials have clinical value? J Clin Psychopharmacol 1999;19:391-2.
32. International Headache Society. Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. First edition. Cephalalgia 1991;11:1-12.
33. Olesen J, Lipton RB. Migraine classification and diagnosis. International Headache Society criteria. Neurology 1994;44 (Suppl 4):6-10.
34. Pajarón E, Láinez JM, Monzón MJ, Parra J, Peiró C, Sancho J. Validez de los criterios de clasificación de la International Headache Society para la migraña, cefalea de tensión episódica y cefalea tensional crónica. Neurología 1999;14:283-8.
35. Dowson AJ, Massion H, Laínez JM, Cabarrocas X. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia 2002;22:453-61.